Acurex Biosciences key facts
- Operator of a pharmaceutical company intended to halt major neurodegenerative diseases.
- Notable investors include Regents of the University of California, Innovations for Impact, Michael J. Fox Foundation.
- Status: Privately Held (backing).
Who backs Acurex Biosciences
3- ·Watch Acurex Biosciences: the Monday email on marks, rounds and moves
Acurex Biosciences funding rounds
No funding rounds for Acurex Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Acurex Biosciences investors
3 investors are on record for Acurex Biosciences, including Regents of the University of California, Innovations for Impact and Michael J. Fox Foundation.
About Acurex Biosciences
Operator of a pharmaceutical company intended to halt major neurodegenerative diseases. The company specializes in supporting the impairment of mitophagy, by which cells dispose of dysfunctional mitochondria, which plays a significant role in the pathogenesis of PD and other diseases, enabling medical facilities to identify druggable targets responsible for defects in mitophagy.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2019
- Employees
- 12
- Website
- acurex.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Acurex Biosciences doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.